| Zhang10) (2018) | 60(30/30) | 金匮腎氣丸 加 桃紅四物湯 200㎖ Bid | Ginaton (Ginkgo biloba extract) 80㎎ Tid + mecobalain 0.5㎎ Tid | 4 wks | 1. total hearing efficiency2. total effective rates of tinnitus3. effective rates of speech recognition4. changes in TG/t-cho | 1. A: 16.7% / B: 10%(p>0.05)2. A: 73.3% / B: 56.7%(p<0.05)3. A: 93.3% / B: 80%(p<0.05)4. A: 1.92±0.23/5.48±0.25→1.89±0.23/ 5.39±0.20B: 1.95±0.21/5.55±0.24→1.93± 0.21/5.43±0.26(p>0.05) | There was no obvious abnormality in blood routine and liver and kidney function before & after treatment | NR |
| A: 14/16B: 13/17 |
| A: 64.03±3.46B: 63.23±2.42 |
| NR |
| NR |
| Shi11) (2015) | 76(38/38) | 補腎活血湯 1pk Tid | 5% glucose 250㎖ + Coenzyme A100U， ATP 40㎎, vit C 2g, vit B6 0.2g, IV Qd Flunarizine Hydrochloride Capsules 5㎎, oral Qd | 15 Ds | 1. total Hearing effective rate 治愈: hearing is improved to >30㏈, consciously speaking without difficulty, tinnitus disappears顯效: Hearing is improved by > 15dB, conscious hearing has been improved, tinnitus disappeared or reduced, or conscious hearing has not fallen anymore無效: Hearing does not improve or continues to decline, and tinnitus does not decrease. | A: 0/50/39.47/10.53B: 0/47.37/26.32/26.32 (p<0.05) | NR | NR |
| A: 20/18B: 21/17 |
| A: 67.8±4.0B: 68.2±4.5 |
| NR |
| NR |
| Luo12) (2015) | 60(30/30) | 耳聾左慈丸 8pills Tid, oral | Ginkgo Biloba Leaves extract Inj. IV, Qd Flunarizine Hydrochloride Capsules 10㎎ oral, Qd | 2 wks | 1. change of deafness grade2. the level of serum TNF-α//IL-1β/IL-6 | 1. A: 1/10/11/4/4 →9/11/6/0/0 (Improved to normal: 4) B: 2/11/10/3/4 →4/13/6/4/2 (improved to normal: 1)(p<0.05)2. A: 32.62±11.03/75.74±21.41/71.23 ±22.37→20.45±8.48/35.24±12.13/43.20±9.93 B: 34.01±12.17/73.91±22.37/69.71± 24.40→25.95±10.91/43.14±14.15/52.31±11.71 (p<0.05) | NR | NR |
| A: 18/12B: 15/15 |
| A: 67.5±7.1B: 65.1±4.8 |
| NR |
| A: 1/10/11/4/4B: 2/11/10/3/4 |
| Huang13) (2021) | 120(60/60) | (B) +補腎塼精方 1pk Bid | Flunarizine hydrochloride 10㎎ Bid, oral. + Ginko-damo injection 20㎖ Qd, IV | 4 wks | 1. tinnitus evaluation scale(I/II/III/IV/V), N2. Oxidative stress indicator level (T-AOC/GSH-Px/SOD/MDA)3. Quality of life(SF-36 scale) | 1. A: 0/16/23/15/6→21/27/8/4/0B: 0/15/24/14/7→12/24/14/8/22. A: 5.48±1.35/103.26±15.49/75.32± 8.27/7.93±1.19→7.34±1.58/138.45±17.63/92.35±11.69/5.74±1.03B: 5.56±1.29/105.37±15.79/74.83±9.15/7.89±1.26→6.67±1.42/119.68±15.79/86.52±10.79/6.72±1.093. A: 61.18±10.32/64.26±9.13/76.32±8.35/62.27±9.58→81.46±9.97/79.83±10.39/78.64±11.22/77.23±8.43B: 62.43±11.78/62.79±9.34/75.49±9.56/63.37±9.25→73.68±12.25/71.86±10.19/77.69±10.13/72.06±7.47 | A : mild nausea(2), dizziness(1) B : mild nausea(3), dizziness(1) (x2=0.152，p=0.697) | NR |
| A: 24/34B: 28/32 |
| A: 68.29±2.34B: 68.45±2.28 |
| A: 5.32±1.67yrB: 5.38±1.65yr |
| NR |
| Zhang9) (2019) | 128(64/64) | (B)+補腎通竅湯加减 (dose NR) | 5% glucose 250㎖+ Ginkgo biloba extract inj. 87.5㎎ IV | 2 wks | 1. total Hearing effective rate 治愈: Hearing improvement to normal level OR the level before the illness顯效: Hearing improvement to≥30㏈ in each frequency有效: Hearing improvement to 15-30㏈ in each frequency無效: Hearing improvement to <15㏈ in each frequency | A: 57.8%B: 35.9% A>B(p<0.05) | Allergic & gastrointestinal reactions (NR) | 1mon A: 75.0% B: 54.7% |
| A: 34/30B: 35/29 |
| A : 67.8B: 65.6 |
| NR |
| A : 12/42/8/2/0B: 10/40/10/4/0 |
| Yang14)(2013) | 81(27/29/25) | (B1)+益腎治聾顆粒 1 sachet Tid | B1: Ginkgo Biloba extract Inj. + Oxiracetam Inj. IV Qd B2 : 益腎治聾顆粒 1 sachet Tid | 2 wks | 1. Electrical audiometry testing (same as Zhang(2019))2. tinnitus effective rate3. SAS/SDS testing | 1. A: 0/0/4/23B1: 0/0/2/27B2: 0/0/0/25(p>0.05)2. A : 74.04% B1: 51.72% B2: 8.0%3. A: 52.45±3.52/16.73±2.24→43.26± 3.34/13.16±1.78(p<0.05)B1: 50.32±3.67/15.68±2.22→46.63±3.44/13.78±1.63(p<0.05)B2: 51.18±3.24/16.74±2.56→50.54±3.48/16.43±2.27(p>0.05) | NR | NR |
| A: 13/14B1: 15/14B2: 13/12 |
| A: 68.13±4.76B1: 67.73±5.03B2: 68.20±5.47 |
| NR |
| A: 2/10/12/2/1B1: 2/12/13/1/1B2: 3/9/11/2/0 |
| Li15) (2012) | 67(35/32) | (B) +固腎培元方 1pk Bid | Golden theragpam 1T Qd, Tanakan 40㎎1T Tid | 2 wks | Audiometry improvement effective rate (same as Zhang(2019)) | A: 0/5/17/13(total 62.9%)B: 0/3/14/15(total 53.1%) (p<0.05) | NR | NR |
| A: 20/15B: 18/16 |
| A: 72.3B: 68.7 |
| A: 6-25yrsA: 5-23yrs |
| A:8/10/10/4/3B: 5/8/10/6/3 |
| Chai16) (2000) | 140(60/40/40) | 聰耳丸 6g Tid, oral | B1: Vitamin B1 20㎎, Tid, Flunarizine hydrochloride 12㎎ Qd, oral B2: 耳聾左慈丸 3g Tid, oral | 4 wks | 治愈: Hearing improvement to normal level in each frequency(500-800㎐) 顯效: Hearing improvement to≥30㏈ in each frequency有效: Hearing improvement to≥10㏈ in each frequency無效: Hearing improvement to<10㏈ in each frequency | % (治愈/顯效/有效/無效) A: 3.33/21.67/50/25 B1: 0/5/32.5/62.5 B2: 0/2.5/45/52.5 A>B1(p<0.001) A>B2(p<0.01) | NR | NR |
| A: 36/24B1: 27/13B2: 36/24 |
| A: 44-75B1: 47-72B2: 44-75 |
| A: 0.25-16yrB1: 0.25-12yrB2: 20.5-17yr |
| A: 23/25/0/12/0B1: 11/17/0/12/0B2: 15/18/0/7/0 |
| Zhong17 (2011) | 42(22/20) | 六味地黄丸 加 骨碎補, 丹蔘加味方 1pk Tid | 耳聾左慈丸 8pills Tid | 30 Ds | 1. Mean deafness rank(hearing loss/word recognition)2. Mean tinnitus rank3. Quality of life(HHIE-S) (Self-assessment affective disorder/Social function/total score) | 1. A: 20.48/20.07→20.48/20.16B: 22.63/23.08→22.18/22.98 (p>0.05)2. A: 26.73→25.27B: 15.75→17.35A>B(p<0.05)3. A: 17.90±8.82/27.72±15.29/45.63±23.72→13.45±7.22/21.90±12.36/35.36±18.99B: 21.00±7.77/28.00±10.25/49.00± 17.33→17.40±8.18/24.70±11.33/42.30±19.24 A>B(p<0.05) | NR | 3mons (A/B)1. same2. 23.45/19.353. A(13.36±7.18/21.72±12.25/35.09±18.86)/B(17.40±8.18/24.70±11.33/42.30±19.24) |
| A: 12/10B: 9/11 |
| A: 66.04±5.69B: 65.85±4.90 |
| NR |
| A: 7/11/0/4/0B: 5/10/0/5/0 |
| Whang18) (2016) | 60(30/30) | 活血返聪湯 1pk Bid | 杞菊地黄丸 1pill Bid | 4 wks | Audiometry improvement (same as Zhang(2019)) | A: 0/30/46.6/23.4B: 0/6.6/40/53.4 (p=0.017) | No adverse events | NR |
| A: 16/14B: 15/15 |
| A: 64.83±2.67B: 65.93±2.57 |
| (0-1/1-2/2-3/>3yrs)A: 18/6/1/5B: 16/8/2/4 |
| A: 2/12/14/2/0B: 3/13/12/2/0 |
| Dong19) (2012) | 60(30/30) | 通氣散 合 耳聾左慈丸 1pk Bid | 杞菊地黄丸 6g Tid, 复方丹蔘片 1.08g Tid | 15 Ds | 1. the total effective rate of hearing improvement (same as Zhang(2019)) 2. the effective rate of groups with/without accompanied symptoms① tinnitus/non-tinnitus② dizziness/non-dizziness | 1. A: 6/9/7/8(73.3%)B: 0/6/7/17(46.7%) (p<0.05) 2. A: ① 63.2/90.9% (p>0.05)② 69.2/76.4% (p>0.05)B: ① 35.0/70.0% (p>0.05)② 50.0/50.0% (p>0.05) | No adverse event in two groups | 1 mon (NR) |
| A: 18/12B: 13/17 |
| A: 58.50±6.183B: 61.00±6.316 |
| A: 3.00±1.64yrsB: 4.00±1.85yrs |
| A: 4/13/11/2/0B: 2/11/13/4/0 |
| Wu20) (2017) | 90(45/45) | Ginkgo Biloba extract 0.9% 100ml IV Bid +耳聾左慈丸 6g Tid | 耳聾左慈丸 6g Tid | 2 wks | 1. platelet aggregation rate/ plasma viscosity/fibrinogen2. whole blood viscosity at high/low shear rate/ erythrocyte sedimentation rate | 1. A: 82.36±6.12/1.98±0.12/4.36±0.31→35.12±3.12/1.32±0.21/2.79±0.10B: 83.89±212/2.02±0.35/4.32±0.21→39.45±6.12/1.65±0.41/3.25±0.69(p<0.05)2. A: 13.26±3.12/5.16±0.39/46.23±3.19 → .89±1.02/3.02±0.21/20.13±2.56B: 13.35±4.12/5.16±0.37/46.12±6.12→10.23±3.19/3.45±0.12/25.46±3.19 (p<0.05) | NR | NR |
| A : 16/29B: 17/28 |
| A: 65.27±4.53B: 63.12±4.39 |
| NR |
| NR |